Humacyte (HUMAW) Competitors $0.98 -0.01 (-0.84%) As of 03:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsSEC FilingsTrends HUMAW vs. ATNFW, LBPSW, AARD, AEHAW, AIMDW, ALVOW, ACABW, BFRIW, BTMDW, and BCTXWShould you be buying Humacyte stock or one of its competitors? The main competitors of Humacyte include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aardvark Therapeutics (AARD), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), Alvotech (ALVOW), Atlantic Coastal Acquisition Corp. II (ACABW), Biofrontera (BFRIW), biote (BTMDW), and BriaCell Therapeutics (BCTXW). These companies are all part of the "pharmaceutical products" industry. Humacyte vs. 180 Life Sciences 4D pharma Aardvark Therapeutics Aesther Healthcare Acquisition Ainos Alvotech Atlantic Coastal Acquisition Corp. II Biofrontera biote BriaCell Therapeutics Humacyte (NASDAQ:HUMAW) and 180 Life Sciences (NASDAQ:ATNFW) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, community ranking, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability. Does the MarketBeat Community believe in HUMAW or ATNFW? Humacyte and 180 Life Sciences both received 0 outperform votes by MarketBeat users. CompanyUnderperformOutperformHumacyteN/AN/A180 Life SciencesN/AN/A Which has stronger valuation & earnings, HUMAW or ATNFW? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHumacyteN/AN/AN/AN/AN/A180 Life SciencesN/AN/AN/AN/AN/A Is HUMAW or ATNFW more profitable? Company Net Margins Return on Equity Return on Assets HumacyteN/A N/A N/A 180 Life Sciences N/A N/A N/A Does the media prefer HUMAW or ATNFW? In the previous week, Humacyte's average media sentiment score of 0.00 equaled 180 Life Sciences'average media sentiment score. Company Overall Sentiment Humacyte Neutral 180 Life Sciences Neutral SummaryHumacyte and 180 Life Sciences tied by winning 0 of the 0 factors compared between the two stocks. Remove Ads Get Humacyte News Delivered to You Automatically Sign up to receive the latest news and ratings for HUMAW and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HUMAW vs. The Competition Export to ExcelMetricHumacyteBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$121.09M$5.73B$8.12BDividend YieldN/A3.69%4.41%4.09%P/E RatioN/A3.2624.4819.28Price / SalesN/A4,516.19402.1289.09Price / CashN/A13.0138.1134.64Price / BookN/A35.096.904.38Net IncomeN/A-$87.82M$3.18B$247.04M7 Day Performance8.78%0.64%0.81%2.01%1 Month Performance-18.42%59.40%0.40%-8.31%1 Year Performance31.41%85.14%13.84%5.72% Humacyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HUMAWHumacyteN/A$0.98-0.8%N/A+32.1%$0.00N/A0.00150Gap DownATNFW180 Life SciencesN/A$0.01+1.2%N/A-10.6%$0.00N/A0.007Positive NewsLBPSW4D pharmaN/AN/AN/AN/A$0.00$522,000.000.00N/AAARDAardvark TherapeuticsN/A$10.42+1.6%$30.50+192.7%N/A$0.00N/A0.0018Gap UpAEHAWAesther Healthcare AcquisitionN/A$0.02-7.9%N/A-83.5%$0.00N/A0.002Gap DownAIMDWAinosN/A$0.09-21.1%N/A+153.4%$0.00$40,633.000.0040Gap UpALVOWAlvotechN/A$1.50+26.1%N/A-55.2%$0.00$391.87M0.004ACABWAtlantic Coastal Acquisition Corp. IIN/A$0.05flatN/AN/A$0.00N/A0.004BFRIWBiofronteraN/A$0.06-0.2%N/A+10.1%$0.00$35.36M0.0070Positive NewsGap DownBTMDWbioteN/A$0.07-1.4%N/AN/A$0.00$193.06M0.00N/ABCTXWBriaCell TherapeuticsN/A$0.10-1.6%N/A-94.0%$0.00N/A0.008Gap Up Remove Ads Related Companies and Tools Related Companies ATNFW Competitors LBPSW Competitors AARD Competitors AEHAW Competitors AIMDW Competitors ALVOW Competitors ACABW Competitors BFRIW Competitors BTMDW Competitors BCTXW Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HUMAW) was last updated on 3/19/2025 by MarketBeat.com Staff From Our Partners$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredMusk’s real agenda in D.C. In this urgent exposé, you’ll discover… How Elon and Donald Trump are quietly drawing a radical new map of ...Porter & Company | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Humacyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Humacyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HUMAW Stock Alerts